Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2

Conditions

Melanoma 2Recurrence 1

Interventions

Cyclophosphamide 909Carboplatin 787pembrolizumab 744Paclitaxel 742Cisplatin 709Bevacizumab 706Gemcitabine 619Docetaxel 579Rituximab 548Radiotherapy 541Dexamethasone 511Nivolumab 488Doxorubicin 444Fluorouracil 392Capecitabine 376Etoposide 358Pemetrexed 337Cytarabine 335Oxaliplatin 333Lenalidomide 328Prednisone 326fludarabine phosphate 316Erlotinib Hydrochloride 314Trastuzumab 300Leucovorin 299fludarabine 296Vincristine 287Filgrastim 284Bortezomib 284Cetuximab 276

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Has results × Rose Bengal × Clear all
NCT02288897 2022-01-19

PV-10 vs Chemotherapy or Oncolytic Viral Therapy for Treatment of Locally Advanced Cutaneous Melanoma

Provectus Pharmaceuticals

Phase 3 Terminated
20 enrolled 13 charts
Dermatologic

Melanoma, Recurrence

NCT00521053 2014-08-25

Phase 2 Study of Intralesional PV-10 for Metastatic Melanoma

Provectus Pharmaceuticals

Phase 2 Completed
80 enrolled 14 charts
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡